文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病中的高血压——2023年治疗标准

Hypertension in chronic kidney disease-treatment standard 2023.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该综述总结慢性肾脏病(CKD)合并高血压的治疗标准:准确测量血压是管理第一步,限钠常被忽视但可改善血压控制;极高白蛋白尿时国际指南一致强烈推荐血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂为一线降压药;难治性高血压推荐加用螺内酯,但高钾血症风险限制其在中重度CKD中的使用;氯噻酮对4期CKD未控制高血压有效并可减少高钾血症以联用螺内酯;新型药物需更大更长试验验证。

要点

  • 准确测量血压是CKD高血压诊断和管理的关键第一步。
  • 极高白蛋白尿时国际指南一致强烈推荐ACEI或ARB为一线降压药。
  • 4期CKD未控制高血压可使用氯噻酮,联用螺内酯需密切监测。

核心结论

  • CKD高血压治疗以准确测压、限钠为基础,极高白蛋白尿者强烈推荐ACEI或ARB,难治性高血压推荐加用螺内酯,氯噻酮为4期CKD未控制高血压提供替代选择,新型药物需更大更长试验验证。

研究设计与样本

  • 综述,回顾CKD患者高血压的当前治疗标准及病理生理、诊断、结局预测和管理的新进展。

主要发现

  • 饮食限钠常被忽视,但可改善血压控制,尤其在使用肾素-血管紧张素系统阻断剂的患者中。
  • 极高白蛋白尿时,国际指南一致且强烈推荐血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂作为首选降压药。
  • 长效二氢吡啶类钙通道阻滞剂和利尿剂是合理的二线和三线治疗选择。
  • 难治性高血压指南推荐在基线降压方案中加用螺内酯,但高钾血症风险限制其在 moderation-to-advanced CKD 中的广泛使用。
  • CLICK试验证据表明,噻嗪样利尿剂氯噻酮对4期CKD未控制高血压(包括难治性高血压)有效,并可减轻高钾血症风险以联用螺内酯,但需密切监测血压和肾功能。

关键数值与推荐

  • 极高白蛋白尿时,国际指南一致且强烈推荐使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂作为首选降压药。
  • 难治性高血压,指南推荐在基线降压方案中加用螺内酯。
  • 长效二氢吡啶类钙通道阻滞剂和利尿剂为合理的二线和三线治疗选择。

临床怎么用

  • 准确测量血压是CKD高血压诊断和管理的必要第一步。
  • 饮食限钠可改善血压控制,尤其在使用肾素-血管紧张素系统阻断剂的患者中。
  • 极高白蛋白尿患者首选血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。
  • 难治性高血压可加用螺内酯,但中重度CKD需注意高钾血症风险。
  • 4期CKD未控制高血压可考虑氯噻酮,联用螺内酯时需密切监测血压和肾功能。

局限性

  • 螺内酯相关高钾血症风险限制其在中重度CKD患者中的广泛使用。
  • 氯噻酮与螺内酯联用需要仔细监测血压和肾功能以预防不良事件。
  • 新型药物需更大规模和更长期临床试验证明安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertension is very common and remains often poorly controlled in patients with chronic kidney disease (CKD). Accurate blood pressure (BP) measurement is the essential first step in the diagnosis and management of hypertension. Dietary sodium restriction is often overlooked, but can improve BP control, especially among patients treated with an agent to block the renin-angiotensin system. In the presence of very high albuminuria, international guidelines consistently and strongly recommend the use of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker as the antihypertensive agent of first choice. Long-acting dihydropyridine calcium channel blockers and diuretics are reasonable second- and third-line therapeutic options. For patients with treatment-resistant hypertension, guidelines recommend the addition of spironolactone to the baseline antihypertensive regimen. However, the associated risk of hyperkalemia restricts the broad utilization of spironolactone in patients with moderate-to-advanced CKD. Evidence from the CLICK (Chlorthalidone in Chronic Kidney Disease) trial indicates that the thiazide-like diuretic chlorthalidone is effective and serves as an alternative therapeutic opportunity for patients with stage 4 CKD and uncontrolled hypertension, including those with treatment-resistant hypertension. Chlorthalidone can also mitigate the risk of hyperkalemia to enable the concomitant use of spironolactone, but this combination requires careful monitoring of BP and kidney function for the prevention of adverse events. Emerging agents, such as the non-steroidal mineralocorticoid receptor antagonist ocedurenone, dual endothelin receptor antagonist aprocitentan and the aldosterone synthase inhibitor baxdrostat offer novel targets and strategies to control BP better. Larger and longer term clinical trials are needed to demonstrate the safety and efficacy of these novel therapies in the future. In this article, we review the current standards of treatment and discuss novel developments in pathophysiology, diagnosis, outcome prediction and management of hypertension in patients with CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Georgianos PI, Agarwal R. Hypertension in chronic kidney disease-treatment standard 2023. Nephrol Dial Transplant. 2023. PMID: 37355779. doi:10.1093/ndt/gfad118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。